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Abstract 
Background: Atrio-ventricular block (AVB) is a rare finding in young or middle-aged 
adults, often leading to pacemaker implantation (PM) without further investigation. We 
sought to assess the diagnostic role of cardiovascular magnetic resonance (CMR) in 
young and middle-aged adults with high-grade AVB. 
Methods: We consecutively enrolled young-middle aged (18-65yrs) patients with high 
grade AVB referred to CMR after standard clinical assessment (history, 
electrocardiogram and cardiac rhythm monitoring) prior to PM implantation.  Cine and 
post-contrast imaging were performed in a 1.5T scanner.  
Results: 34 patients (59% male, mean age 42 ±12 years) with high grade AVB were 
referred to CMR for suspected ischemic heart disease (IHD)(n=4) and non-ischemic heart 
disease (NIHD)(n=20); no clear cause was found in 9 patients prior to CMR and 1 patient 
had suspected lung disease. A pathologic substrate was found on CMR in 15 patients 
(44%), while a structurally normal heart was reported in 18 (53%). Non-specific findings 
were reported in 1 patient (3%). There was a fair agreement between CMR and 
echocardiographic findings (Cohen’s kappa 0.243), and CMR provided an entirely new 
diagnosis in 34% of patients. As compared to the standard clinical assessment, CMR had 
an additional role in 65% of patients and guided further testing (genetic testing, extra-
cardiac imaging) in 9%. 
Conclusions: CMR found a pathologic substrate in 44% of patients, mainly NIHD 
(32%). Half of patients (53%) had a structurally normal heart. When added to the 
standard clinical assessment, CMR had an incremental diagnostic role in two thirds of 
patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Atrio-ventricular block (AVB) typically shows a bimodal distribution, with a major peak 
in incidence in the elderly, commonly due to degeneration of the conduction system, and 
the other in infancy and early childhood, when it is mainly congenital. While the lower-
grade AVB is considered benign as it can be observed in up to 1–2% of healthy young 
people, especially during sleep [1], the higher-grade AVB, such as second degree Mobitz 
II or complete AVB, is expression of the severity of the underlying cause and more often 
requires a pacemaker (PM) implantation [2]. Higher grade AVB is uncommon in young 
or middle-aged adults, but when identified it poses a dilemma, both in terms of diagnosis 
and clinical management. According to international guidelines [2], patients are 
frequently offered permanent PM implantation without further investigation, and up to 3-
5% of all the patients undergoing PM implantation for AVB are aged 18-55 years [3,4]. 
PM implantation in young adults is generally recognized as a safe procedure, but it has 
been associated with peri- and post-procedural complications [5,6]. Ischemic, 
autoimmune and infiltrative diseases are the recognized causes of complete AVB in 
young or middle-aged adults [5,6]. Correct identification of the underlying 
pathophysiologic mechanism has a great impact both on therapeutic strategies and on the 
prognosis of AVB [4,7]. International guidelines recommend the clinical assessment of 
patients, comprehensive of clinical history, ECG and cardiac rhythm monitoring, but do 
not provide indications with regards to the need for cardiac imaging prior to treatment [2]. 
Cardiac magnetic resonance (CMR) is a well-established diagnostic imaging technique 
with increasing applications in clinical practice: CMR represents the gold standard for the 
assessment of biventricular volumes and function [8] and offers a uniquely advanced, 
non-invasive, myocardial tissue characterization, providing an accurate assessment of 
myocardial fibrosis by late gadolinium enhancement, which has been validated against 
histology [9,10] . We sought to assess the diagnostic role of CMR in young and middle-
aged adults with high-grade AVB. 
Materials and Methods 
We retrospectively enrolled consecutive young and middle-age patients (aged 18-65 
years) referred for CMR prior to PM implantation because of higher-grade AVB. Higher-
grade AVB was defined as advanced II degree AVB (Mobitz II AVB, 2:1 AVB) and 
complete or III degree AVB. All patients underwent a 1.5T CMR (Avanto, Siemens 
Healthcare, Germany), with a comprehensive protocol that included long and short axis 
cine and late gadolinium enhancement (LGE) images.  Steady state free precession 
sequences were performed to acquire the long and short axis cine images; typical 
parameters were TR 38 ms, TE 1.07 ms, flip angle 80°, slice-thickness 8 mm, inter-slice 
gap 0 mm, bandwidth 930 Hz/Px, voxel size 2.0x2.0x8.0 mm and temporal resolution 
≤45 ms between phases. For LGE imaging, a standard inversion recovery gradient-echo 
sequence was adopted. The LGE images were acquired 10-15 minutes after intravenous 
injection of 0.1 mmol/Kg of body weight of gadolinium-chelate contrast agent (Gadovist 
1.0 mmol/ml, Bayer-Schering, Berlin, Germany) in identical short-axis planes to cine 
images, using an inversion recovery prepared breath-hold gradient-echo technique. 
Typical image parameters were TR 700 ms, TE 3.15 ms; flip angle 25°; slice thickness 
8.0 mm, no interslice gap, bandwidth 140 Hz/Px and voxel size 2.0 × 1.5 × 8.0 mm. The 
inversion time was progressively optimized to null normal myocardium (typical values, 
250–350 ms). Each slice was obtained during a breath-hold of 10–15 s depending on the 
patient’s heart rate.  
Ventricular function was assessed with dedicated software (Circle Cardiovascular 
Imaging, Calgary, Canada), by tracing endo- and epicardial borders on each short axis 
cine slice in end-diastole and end-systole. All volumes measurements were indexed to 
body surface area. The presence/absence, localization, and distribution pattern of LGE 
were assessed visually by a SCMR/ESC level 3 certified individual with > 10 years of 
experience. Pattern and extent of LGE were assessed by using short- and long-axis views 
and were defined as present only if they were detectable in two orthogonal planes. The 
pattern of LGE distribution was defined as subendocardial or transmural, if involving 
<50% or ≥50% of wall thickness, respectively, and as mid-wall/epicardial if 
patchy/spotty intra-mural or sub-epicardial enhancement was detected. The presence of 
LGE at the right ventricle/left ventricle insertion points, in the absence of other LGE 
distribution patterns, was defined as non-specific findings, as its diagnostic and 
prognostic meaning is still unclear. All the analysis was carried out in accordance with 
the recommendation of the Society for Cardiovascular Magnetic Resonance [11]. Based 
on a standard clinical assessment, including clinical history, ECG and cardiac rhythm 
monitoring, all patients were referred with a pre-CMR working diagnosis, classified as 
ischemic heart disease (IHD), non-ischemic heart disease (NIHD), normal heart and 
unknown cause. The study was reviewed by the local Institutional Research and 
Innovation Department and in view of the retrospective design of the study, formal 
ethical approval was waived off. All patients gave written informed consent.  
Statistical analysis 
Continuous and categorical variables are expressed as mean±SD or median (IQR), and n 
(%), respectively. Categorical variables were compared by using the chi-square test or 
Fisher exact test, as appropriate. Inter-rater agreement for categorical variables was 
assessed by Cohen’s kappa coefficient. A p-value of <0.05 was considered statistically 
significant. Data were analysed with SPSS® version 23 (IBM®).  
Results 
We consecutively enrolled thirty-four patients (59% male, mean age 42 ±12 years, 
minimum-maximum 21-61 years) referred to CMR prior to PM implantation secondary 
to higher grade AVB. Twenty-two patients (65%) had evidence of complete AVB and 12 
patients (35%) had second degree Mobitz II AVB. Twenty-three patients (68%) showed 
intermittent high grade AVB on 24 hours Holter monitoring or on implantable loop 
recorder monitoring. Eleven patients (32%), all but one presenting with III degree AVB, 
were admitted to hospital following syncope; they were all haemodynamically stable and 
underwent CMR as inpatients. Based on the standard clinical assessment, 4 patients were 
referred for suspected ischemic heart disease (IHD) and 20 for suspected NIHD; no clear 
cause was identified in 9 patients prior to CMR and one patient had suspected interstitial 
lung disease. Median LVEF was 64% (IQR 58-68), median indexed left ventricular end-
diastolic volume (LVEDV) was 88 ml/m2 (IQR 77-109) and median indexed left 
ventricular end-systolic volume (LVESV) was 31 ml/m2 (IQR 27-54). On tissue 
characterization, LGE was found in twelve patients (35%), mainly with a mid-
wall/epicardial pattern (7/12 patients, 58%); LGE had a septal distribution in 5 patients 
(42%). Based on CMR findings, a pathologic substrate was found in 15 patients (44%): 4 
patients (12%) were diagnosed with IHD and 11 (32%) with NIHD. A structurally normal 
heart was found in 18 patients (53%) and non-specific findings were reported in 1 patient 
(3%). Among patients presenting findings consistent with NIHD, myocarditis was the 
most common (5 patients, of which 2 were diagnosed with cardiac sarcoidosis, Figure 1A 
and B), followed by athlete’s heart and valvular heart disease (moderate aortic 
regurgitation and severe pulmonary regurgitation) which were each reported in 2 patients, 
respectively; dilated cardiomyopathy (Figure 1C and D) and left ventricular non-
compaction were each found in 1 patient. CMR findings are listed in Table 1. 
Standard clinical assessment vs CMR findings 
Based on clinical and family history and on ECG findings, IHD was suspected prior to 
cardiac imaging in 4 patients and NIHD in 20 patients; no clear cause could be identified 
in 9 patients and 1 patient was diagnosed with suspected lung disease. CMR had an 
additional role in re-defining the final findings in 22/34 (65%) patients, mainly by re-
defining the final diagnosis in 4 patients and by ruling out an underlying structural heart 
disease in 18 patients (Table 2). Among the 20 patients with a pre-imaging diagnosis of 
suspected NIHD, CMR diagnosed IHD in 2 patients and found a structurally normal heart 
in 9 patients. Among the 9 patients with no clear cause for AVB prior to imaging, CMR 
found a structurally normal heart in 7 patients and NIHD in one.  
Diagnostic performance of CMR and TTE 
Trans-thoracic echocardiogram (TTE) data were available in 29/34 patients (85%). A 
pathologic substrate was found on TTE in 3/29 patients (10%): one patient (3%) was 
diagnosed with IHD and 2 (7%) with NIHD. There was no significant difference between 
the ability of CMR and TTE to identify a pathologic substrate, but there was a trend in 
favour of CMR (15/34 vs 3/29, p=0.539). A structurally normal heart was found on TTE 
in 21 patients (73%) and non-specific findings were reported in 5 patients (17%). CMR 
and TTE provided the same diagnosis in 17/29 patients (59%) with an overall fair 
agreement (Cohen’s kappa 0.243, p=0.019); CMR had mainly a role in re-defining 
patients diagnosed with normal heart and those with non-specific findings on TTE, 
overall providing a new diagnosis in 10/29 patients (34%). Out of 21 patients diagnosed 
with normal heart on TTE, 5 (24%) received a different diagnosis on CMR: one patient 
had findings of IHD and 4 of NIHD. CMR was diagnostic in all 5 patients with non-
specific findings on TTE: three patients had findings consistent with NIHD, one with 
IHD and one with structurally normal heart (Table 3).  
Discussion  
The main findings of our study were: 1) CMR identified an underlying pathologic 
substrate in nearly half of patients, 2) the most prevalent underlying conditions was 
NIHD (32%); 3) CMR demonstrated a significant incremental diagnostic value (in 65% 
of patients) when added to standard clinical work-up of patients with AVB; 4) when 
added to transthoracic echocardiography CMR provided an entirely new diagnosis in 
34% of patients. 
Higher grade AVB is rare in young or middle-aged adults and the underlying etiologic 
mechanisms are multiple and different from the degenerative process mainly responsible 
for AVB in the elderly [12]. To the best of our knowledge this is the largest study 
investigating the role of CMR in patients with high-grade AVB, and its added value to 
the current standard clinical practice. In our cohort, CMR could identify an underlying 
pathologic substrate in nearly half of patients (44%). We found a 12% incidence of IHD, 
which is in keeping with previous studies on middle-aged (45-65 years) patients 
presenting with AVB [13] and on patients with severe LV systolic dysfunction after acute 
myocardial infarction [14]. More than a third (32%) of our patients had evidence of 
NIHD on CMR; as confirmed by endomyocardial biopsy (EMB) studies in patients with 
high grade AVB [15-17], we have also found that myocarditis is the most common non-
ischemic cardiomyopathy. It has been shown that Lamin A/C gene mutation in dilated 
cardiomyopathy accounts for 33% of AVB [18] cases, but similar scenarios are also seen 
in cases of LV non-compaction and hypertrophic cardiomyopathy, as also confirmed in 
our cohort. Infiltrative diseases are frequently associated with AVB, which often 
represents the first and most common clinical manifestation, as in the case of cardiac 
sarcoidosis [19]. Although cardiac sarcoidosis commonly results in AVB, it is a rare 
disease, and its prevalence in the spectrum of AVB is not well known [20]. Based on 
CMR findings we diagnosed cardiac sarcoidosis in 2 patients (6%, 18% of the NIHD). 
Other causes of high grade AVB in young-middle aged patients include cardiac 
amyloidosis [21,22] and can be rarely encountered among trained athlete’s [23,24], where 
it is usually considered pathological.  
CMR vs standard of care clinical assessment 
In patients presenting with AVB, international guidelines recommend a clinical 
assessment, comprehensive of clinical history, ECG and cardiac rhythm monitoring, but 
there is no indication with regards to the need for cardiac imaging prior to treatment [2]. 
Patients are thus often offered a PM implantation without further investigation, although 
the underlying pathology has important implications on prognosis. CMR showed an 
additional role in 65% of patients when added to the standard clinical assessment, mainly 
by re-defining the final diagnosis in 4 patients and by ruling out an underlying structural 
heart disease in 18 patients (Table 2). European guidelines on cardiac pacing [2] do not 
recommend TTE in the work up of high-grade AVB patients. Nevertheless, nearly all of 
our patients (85%) underwent a TTE in addition to the standard clinical assessment. TTE 
could identify a pathologic substrate in 10% of patients, which was lower compared to 
CMR (44%) although it did not reach statistical significance, most likely because of the 
small sample size. The agreement between TTE and CMR findings was fair, and CMR 
provided an entirely new diagnosis in 10/29 (34%) patients, mainly by re-defining 
diagnosis among patients with a structurally normal heart (5/21, 24%) and being 
diagnostic in all 5 patients with non-specific findings on TTE.  
Clinical Implications 
Although CMR did not change the final treatment strategy with regards to AVB, as all 
patients received a PM, information provided by CMR, as compared to both the standard 
clinical assessment and TTE, had a clinical impact in patients’ management with direct 
implications on their treatment strategies.  
The superior diagnostic capability of CMR in our cohort was mainly related to the 
analysis of LGE sequences: LGE was found in 35% of patients, mainly with a non-
ischemic distribution pattern (58%) and with a septal location in 42% of patients. It is 
well established that LGE distribution pattern allows non-invasive identification of the 
structural aetiology of cardiomyopathies [25-27], with a diagnostic accuracy in some 
cases exceeding that of trans-thoracic echocardiogram and even of EMB [28]. The 
advanced tissue characterization provided by CMR has also been shown to allow the 
identification of genetic variants of common cardiomyopathies [29,30]: a recent study by 
Holmstrom et al. demonstrated that 88% of asymptomatic or mildly symptomatic carriers 
of Lamin A/C (LMNA) mutations causing dilated cardiomyopathy had typical 
myocardial fibrosis, involving the mid-myocardium of the basal septum (Figure 1D, 
white arrow) [29]. The fibrosis was observed in all individuals with an AV conduction 
defect and LGE-pattern was typically linear with involvement of less than 50% of the 
area of the segment. In our series, a patient showed mildly dilated LV with the typical 
mid-wall fibrosis of the basal antero-septum on CMR (Figure 1D, white arrow): late 
genetic testing was positive for LMNA mutation. Moreover, in our patients cohort, CMR 
diagnosis of cardiac sarcoidosis triggered further testing, leading to the finding of extra-
cardiac manifestations of the disease in both patients.  
Finally, it has been shown that CMR is able to detect myocardial infarction in a non-
negligible proportion of patients (approximately one third) in which the diagnosis was 
missed on non-CMR imaging [31]: although this was not the case in our patients’ cohort, 
finding evidence of unknown IHD on CMR in patients with high-grade AVB might lead 
to diagnostic invasive coronary angiogram, as underlying coronary artery disease can 
explain the conduction disorder [13].   
Study Limitations 
The main limitation of the present study is the limited number of patients; nevertheless, 
AVB in this age group (18-65 years) is a very rare condition and to our knowledge, this is 
the first and largest series of young and middle-aged patients with high-grade AVB 
referred for CMR. Half of our patients were found to have structurally normal hearts. It is 
acknowledged that transient tissue damage, in the form of reversible myocardial oedema, 
as in the few Tako-Tsubo cases reported in literature [32,33], may induce atrio-
ventricular conduction abnormalities; T2-weighted sequences for myocardial oedema 
were not performed in our cohort, so transient acute tissue damage could not be assessed. 
We might speculate that this aspect might explain the high prevalence of structurally 
normal hearts in our cohort. A structurally normal heart on CMR reflects the absence of 
gross ischemic or non-ischemic abnormalities, but cannot exclude the presence of 
microscopic, ultra-structural abnormalities, which are below the resolution of the 
technique. EMB is the gold standard to assess ultra-structural abnormalities, but carries 
non-negligible complications, and is not routinely performed in clinical practice, and we 
had no histologic data in our patients’ cohort. Finally, LGE imaging accurately allows the 
identification and characterization of focal fibrosis; however, exploring the presence of 
diffuse fibrosis on T1 mapping technique [34] might provide a new insight in the 
aetiology of high-grade AVB. Further studies, to assess tissue characterization with more 
advanced sequences, such as the T1 and T2 mapping, could provide additional insight on 
interstitial changes in this patients’ cohort.  
Conclusions 
In young patients presenting with high grade AVB, CMR demonstrated incremental 
diagnostic yield by identifying a pathologic substrate in 44% of patients. There was a fair 
agreement between CMR and TTE final diagnosis, and CMR provided an entirely new 
diagnosis in 34% of patients. When added to the standard clinical assessment (history, 
ECG and cardiac rhythm monitoring) CMR had an additional diagnostic role in two 
thirds of patients. Our results show that CMR could be a valuable test to be included in 
the clinical work-up of patients with AVB.  
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Tables 
Table 1. CMR Findings 
CMR Findings n (%) 
LVEF, %, median (IQR) 64 (58-68) 
LVEDV, ml/m2, median (IQR) 88 (77-109) 
LVESV, ml/m2, median (IQR) 31 (27-54) 
LGE, n (%) 12 (35) 
Ischemic Heart Disease, n (%) 4 (12) 
Non-ischemic Heart Disease, n (%) 11 (32) 
        - Myocarditis, n  5  
        - Dilated cardiomyopathy, n  1  
        - Athlete’s heart, n  2  
        - Aortic/pulmonary valve regurgitation, n 2  
        - Left ventricular non compaction, n  1  
Structurally Normal Heart, n (%) 18 (53) 
Non-specific Findings, n (%) 1 (3) 
LVEF, left ventricular ejection fraction; LVEDV, left ventricular end-diastolic volume; 
LVESV, left ventricular end-systolic volume; LGE, late gadolinium enhancement. 
Table 2. CMR findings vs standard clinical assessment 
 CMR 
  IHD NIHD Non-specific 
Findings 
Structurally 
Normal Heart  
TOTAL 
 
Standard Clinical 
Assessment 
IHD 2 1 0 1 4 
NIHD 2 9 0 9 20 
Non-specific Findings 0 1 1 7 9 
Other 0 0 0 1 1 
 TOTAL 4 11 1 18 34 
 
Comparison between pre-CMR working diagnosis based on the standard clinical 
assessment (history, ECG and cardiac rhythm monitoring) and CMR findings. Boxes in 
bold show the number of patients that received the same diagnosis before and after CMR. 
CMR, cardiovascular magnetic resonance; IHD, ischemic heart disease; NIHD, non-
ischemic heart disease.  
 
 
 
 
 
  
Table 3. Diagnostic performance of CMR and trans-thoracic echocardiography 
  CMR 
  IHD NIHD Non-specific 
Findings 
Structurally 
Normal Heart  
TOTAL 
 
 
TTE 
IHD  1 0 0 0 1 
NIHD 1 1 0 0 2 
Non-specific Findings 1 3 0 1 5 
Structurally Normal Heart 1 4 1 15 21 
 TOTAL 4 8 1 16 29 
Comparison between CMR and TTE findings. Boxes in bold show the number of patients 
that received the same diagnosis on both imaging modalities. CMR, cardiovascular 
magnetic resonance; TTE, trans-thoracic echocardiogram; IHD, ischemic heart disease; 
NIHD, non-ischemic heart disease.  
 
 
 
 
 
 
 
 
  
Figure Legend 
Figure 1.  
Complete atrio-ventricular block (AVB) (A) in a patient with prominent mid-
wall/epicardial late gadolinium enhancement in the basal inferoseptum (B, black arrow); 
a suspicion of cardiac sarcoidosis was raised and confirmed on laboratory testing. 
Complete AVB (C) in a patient with lamin A/C dilated cardiomyopathy; on late 
gadolinium enhancement sequences, septal enhancement was noted (D, white arrow).  
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